BACE2

Across TCGA pan-cancer cohorts, BACE2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of BACE2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BACE2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BACE2 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.

HNSC and LSCC are the cancer types where BACE2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BACE2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−1.230	<.001	6	view →
LSCC	Male	All	−0.551	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

BACE2–HNSC

Open the HNSC breakdown →